Study S002082

Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily, Both as Monotherapy in Japanese Subjects With Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT02254291
Acronym: SUSTAIN™
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 308
Start: 2014-10-02
Primary completion: 2015-11-11
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: DRUG:semaglutide; DRUG:sitagliptin
Results posted: TRUE
Secondary identifiers: OTHER:U1111-1140-5334; REGISTRY:JapicCTI-142663

Registered primary outcomes

Number of Treatment Emergent Adverse Events (TEAEs) [Weeks 0-30]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0055572	Safety profile of semaglutide in people aged 55 years and over: pooled data from the PIONEER, SUSTAIN and STEP phase 3 clinical programmes Marwan Sabbagh, Alzheimer s & Dementia	2023	Other trial	DOI	cites ClinicalTrials.gov:NCT02254291
R0018529	Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials. Husain M, Cardiovascular diabetology	2020	Randomized trial	PMID 32998732 DOI	cites ClinicalTrials.gov:NCT02254291; registry reference DERIVED:32998732
R0014736	Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes. Seino Y, Diabetes, obesity & metabolism	2018	Randomized trial	PMID 28786547 DOI	cites ClinicalTrials.gov:NCT02254291; registry reference RESULT:28786547